Last reviewed · How we verify
VEGFR2-169 and gemcitabine
At a glance
| Generic name | VEGFR2-169 and gemcitabine |
|---|---|
| Sponsor | Wakayama Medical University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (PHASE1)
- Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2) (PHASE1, PHASE2)
- Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VEGFR2-169 and gemcitabine CI brief — competitive landscape report
- VEGFR2-169 and gemcitabine updates RSS · CI watch RSS
- Wakayama Medical University portfolio CI